MX2014014710A - Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). - Google Patents

Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).

Info

Publication number
MX2014014710A
MX2014014710A MX2014014710A MX2014014710A MX2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A MX 2014014710 A MX2014014710 A MX 2014014710A
Authority
MX
Mexico
Prior art keywords
compounds
alkyltriazole
lpar antagonists
lpar
antagonists
Prior art date
Application number
MX2014014710A
Other languages
English (en)
Inventor
Matthew C Lucas
Yimin Qian
Matthew Michael Hamilton
Achyutharao Sidduri
Stephen Deems Gabriel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014710A publication Critical patent/MX2014014710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Abstract

La presente invención se dirige a compuestos de la fórmula (I): así como sales de los mismos farmacéuticamente aceptables, en donde los sustituyentes son aquellos descritos en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades y trastornos inflamatorios, tal como, por ejemplo, fibrosis pulmonar.
MX2014014710A 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). MX2014014710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
MX2014014710A true MX2014014710A (es) 2015-03-04

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014710A MX2014014710A (es) 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).

Country Status (22)

Country Link
US (1) US9321738B2 (es)
EP (1) EP2864300A1 (es)
JP (1) JP2015520202A (es)
KR (1) KR20150021057A (es)
CN (1) CN104411692A (es)
AU (1) AU2013279512A1 (es)
BR (1) BR112014030685A2 (es)
CA (1) CA2869541A1 (es)
CL (1) CL2014003243A1 (es)
CO (1) CO7131358A2 (es)
CR (1) CR20140525A (es)
EA (1) EA201492285A1 (es)
HK (1) HK1206342A1 (es)
IL (1) IL236088A0 (es)
IN (1) IN2014DN09348A (es)
MA (1) MA37764A1 (es)
MX (1) MX2014014710A (es)
PE (1) PE20142448A1 (es)
PH (1) PH12014502789A1 (es)
SG (1) SG11201407220YA (es)
UA (1) UA109868C2 (es)
WO (1) WO2013189864A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト
CA2869564A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
KR102090231B1 (ko) 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
KR102433588B1 (ko) 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126084A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
KR20200100713A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
JP2021506878A (ja) * 2017-12-19 2021-02-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
KR20200100719A (ko) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
CN111699180A (zh) 2017-12-19 2020-09-22 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
CN112041029A (zh) 2017-12-19 2020-12-04 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑唑类
MX2020006315A (es) 2017-12-19 2022-08-04 Bristol Myers Squibb Co Acidos carbamoil ciclohexilicos ligados a n triazol como antagonistas de acido lisofosfatidico (lpa).
JP7299892B2 (ja) 2017-12-19 2023-06-28 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
KR20200100724A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
US11384055B2 (en) * 2017-12-29 2022-07-12 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
EP3852747B1 (en) * 2018-09-18 2023-05-31 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
KR20210060546A (ko) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
KR20220101137A (ko) * 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
CN103347510B (zh) * 2010-12-07 2015-11-25 艾米拉医药股份有限公司 溶血磷脂酸受体拮抗剂及其在治疗纤维化中的用途
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト

Also Published As

Publication number Publication date
US9321738B2 (en) 2016-04-26
UA109868C2 (ru) 2015-10-12
PH12014502789A1 (en) 2015-02-09
AU2013279512A1 (en) 2014-10-16
CN104411692A (zh) 2015-03-11
KR20150021057A (ko) 2015-02-27
CL2014003243A1 (es) 2015-03-20
MA37764A1 (fr) 2016-01-29
EP2864300A1 (en) 2015-04-29
CA2869541A1 (en) 2013-12-27
IN2014DN09348A (es) 2015-07-17
SG11201407220YA (en) 2014-12-30
US20150133511A1 (en) 2015-05-14
CR20140525A (es) 2015-01-12
WO2013189864A1 (en) 2013-12-27
CO7131358A2 (es) 2014-12-01
BR112014030685A2 (pt) 2017-06-27
HK1206342A1 (en) 2016-01-08
IL236088A0 (en) 2015-02-01
PE20142448A1 (es) 2015-01-28
JP2015520202A (ja) 2015-07-16
EA201492285A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2014DN09434A (es)
IN2014MN02598A (es)
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201591195A1 (ru) Новые хинолоновые производные
MX354102B (es) Derivados de bencimidazol-prolina.
IN2015DN01119A (es)
MX2016002794A (es) Compuestos antiproliferativos.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IN2014DN06869A (es)
UA117154C2 (uk) Антагоністи s1p3
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
PH12017501736A1 (en) Indole derivatives
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders